Immune deficiencies , infection , and systemic immune disorders B-cell reconstitution after lentiviral vector – mediated gene therapy in patients with Wiskott-Aldrich syndrome
暂无分享,去创建一个
L. Naldini | M. Roncarolo | M. C. Castiello | A. Villa | P. Uva | A. Aiuti | L. Sereni | F. Ferrua | I. Brigida | S. Scaramuzza | M. Albert | M. Burg | Francesca Pala | G. Ottaviano
[1] J. Gern,et al. Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients With Wiskott-Aldrich Syndrome , 2014, Pediatrics.
[2] M. van der Burg,et al. Wiskott–Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans☆ , 2014, Journal of autoimmunity.
[3] J. Ritz,et al. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] Michael Rothe,et al. Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity , 2014, Science Translational Medicine.
[5] F. Candotti,et al. Molecular and phenotypic abnormalities of B lymphocytes in patients with Wiskott-Aldrich syndrome. , 2014, The Journal of allergy and clinical immunology.
[6] M. van der Burg,et al. B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients. , 2014, The Journal of allergy and clinical immunology.
[7] F. Candotti. Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases , 2014, International Journal of Hematology.
[8] R. Elhasid,et al. Impact of Conditioning on Outcome of Hematopoietic Stem Cell Transplantation for Wiskott-Aldrich Syndrome , 2013, Journal of pediatric hematology/oncology.
[9] E. Haddad,et al. B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? , 2013, The Journal of allergy and clinical immunology.
[10] E. Meffre,et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation. , 2013, Arthritis and rheumatism.
[11] A. Fischer,et al. Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome. , 2013, Blood.
[12] M. C. Castiello,et al. Autoimmunity in Wiskott–Aldrich Syndrome: An Unsolved Enigma , 2012, Front. Immun..
[13] F. Alt,et al. Wiskott-Aldrich syndrome protein (WASP) and N-WASP are critical for peripheral B-cell development and function. , 2012, Blood.
[14] A. Rolink,et al. BAFF‐R expression correlates with positive selection of immature B cells , 2012, European journal of immunology.
[15] V. Lougaris,et al. Soluble BAFF Levels Inversely Correlate with Peripheral B Cell Numbers and the Expression of BAFF Receptors , 2012, The Journal of Immunology.
[16] E. Meffre. The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases , 2011, Annals of the New York Academy of Sciences.
[17] A. Fischer,et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. , 2011, Blood.
[18] L. Naldini,et al. Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome. , 2011, The Journal of allergy and clinical immunology.
[19] F. Candotti,et al. Nuclear Role of WASp in the Pathogenesis of Dysregulated TH1 Immunity in Human Wiskott-Aldrich Syndrome , 2010, Science Translational Medicine.
[20] C. Cunningham-Rundles,et al. Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. , 2010, Blood.
[21] N. Shan,et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. , 2009, Blood.
[22] M. Cancro. Signalling crosstalk in B cells: managing worth and need , 2009, Nature Reviews Immunology.
[23] K. Schwarz,et al. Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells , 2009, Proceedings of the National Academy of Sciences.
[24] A. Villa,et al. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. , 2009, Blood.
[25] L. Notarangelo,et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. , 2008, Blood.
[26] N. Olsen,et al. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes , 2006, Clinical and experimental immunology.
[27] H. Nossent,et al. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time , 2006, Lupus.
[28] H. Ochs,et al. The Wiskott-Aldrich Syndrome Protein Regulates Nuclear Translocation of NFAT2 and NF-κB (RelA) Independently of Its Role in Filamentous Actin Polymerization and Actin Cytoskeletal Rearrangement1 , 2005, The Journal of Immunology.
[29] E. Remold-O’Donnell,et al. Phenotypic perturbation of B cells in the Wiskott–Aldrich syndrome , 2005, Clinical and experimental immunology.
[30] T. Laín de Lera,et al. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[31] V. Roschke,et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. , 2003, Arthritis and rheumatism.
[32] A. Abo,et al. A Role for Wiskott-Aldrich Syndrome Protein in T-cell Receptor-mediated Transcriptional Activation Independent of Actin Polymerization* , 2001, The Journal of Biological Chemistry.
[33] C. Goodnow,et al. A critical role for complement in maintenance of self-tolerance. , 1998, Immunity.
[34] R de Groot,et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. , 1997, The Journal of pediatrics.
[35] L. Notarangelo,et al. Studies of the expression of the Wiskott-Aldrich syndrome protein. , 1996, The Journal of clinical investigation.
[36] U. Francke,et al. Wiskott–Aldrich Syndrome Protein, a Novel Effector for the GTPase CDC42Hs, Is Implicated in Actin Polymerization , 1996, Cell.
[37] D. Tuveson,et al. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex , 1991, The Journal of experimental medicine.
[38] L. M. Gould,et al. An evaluation of a solid phase red cell adherence test for detecting platelet-associated IgG in immune thrombocytopenia. , 1990, American journal of clinical pathology.
[39] O. Tawfik,et al. A solid-phase red cell adherence test for platelet cross-matching. , 1985, Medical laboratory sciences.
[40] T. Juji,et al. Detection of Platelet Antibodies by a Newly Developed Mixed Agglutination with Platelets , 1981, Vox sanguinis.
[41] L. Harker,et al. The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets , 1980 .
[42] A. Erdei,et al. Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. , 2013, International immunology.
[43] C. von Kalle,et al. Preclinical Safety and Efficacy of Human CD34+ Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[44] J. Stockman. Stem-Cell Gene Therapy for the Wiskott–Aldrich Syndrome , 2012 .
[45] W. Robinson,et al. B cells and transplantation: an educational resource. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[46] A. Fischer,et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. , 2008, Blood.
[47] J. Tschopp,et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. , 2002, The Journal of clinical investigation.
[48] Michael Schlesier,et al. Expansion of CD19(hi)CD21(lo/neg) B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia. , 2002, Immunobiology.
[49] Sue-Jane Lin,et al. Programmed death-1 (PD-1) defines a transient and dysfunctional oligoclonal T cell population in acute homeostatic proliferation , 2007, The Journal of experimental medicine.